REFERENCES
1. World Health Organization. A coordinated global research roadmap: 2019 novel coronavirus. March 2020. https://www.who.int/blueprint/priority-diseases/key-action/Coronavirus_Roadmap_V9.pdf?ua=1 (date of acces: 17.11.2021).
2. Coronavirus spread statistics in Russia. https://coronavirus-monitor.info/country/russia (date of acces: 17.11.2021). (in Russian)
3. Yu C., et al. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: A retrospective matched-pair cohort study. J Med Virol. 2021; 93 (1): 472-80. DOI: https://doi.org/10.1002/jmv.26260
4. Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 13 from 10/14/2021. https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/211/original/BMP-13.pdf (date of access: 17.11.2021). (in Russian)
5. Leneva I., et al. Antiviral activity of umifenovir in vitro against a broad spectrum of coronaviruses, including the novel SARS-CoV-2 virus. Viruses. 2021; 13 (8). DOI: https://doi.org/10.3390/v13081665
6. Wang X., et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020; 6 (1): 28. DOI: https://doi.org/10.1038/s41421-020-0169-8
7. Sanders J.M., et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020; 323 (18): 1824-36. DOI: https://doi.org/10.1001/jama.2020.6019
8. Vankadari N. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents. 2020; 56 (2): 105998. DOI: https://doi.org/10.1016/j.ijantimicag.2020.105998
9. Gao W., et al. Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series. Virol J BioMed Central, 2020; 17 (1): 162. DOI: https://doi.org/10.1186/s12985-020-01428-5
10. Zeng H., et al. Antiviral abidol is associated with the reduction of in-hospital mortality in COVID-19 patients // Cardiol. Discov. 2021. Vol. 1, N 1.P. 37-43. DOI: https://doi.org/10.1097/CD9.0000000000000014
11. Pshenichnaya N.Yu., et al. Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020. Terapevticheskii Arkhiv [Therapeutic Archive]. 2021; 93 (11): 1306-15. DOI: https://doi.org/10.26442/00403660.2021.11.201206 (in Russian)
12. Ghaderkhani S., salami Khaneshan A., Salami A., et al. Efficacy and safety of arbidol in treatment of patients with COVID-19 infection: a randomized clinical trial. Res Sq. Published online 2021. DOI: https://doi.org/10.21203/rs.3.rs-91430/v1
13. Nojomi M., et al. Effect of arbidol (umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis BioMed Central. 2020; 20 (1): 954. DOI: https://doi.org/10.1186/s12879-020-05698-w
14. Yang C., et al. Effectiveness of arbidol for COVID-19 prevention in health professionals. Front Public Heal. 2020; 8: 1-6. DOI: https://doi.org/10.3389/fpubh.2020.00249
15. Zhang J., et al. Potential of arbidol for post-exposure prophylaxis of COVID-19 transmission - a preliminary report of a retrospective cohort study. Curr Med Sci. 2020; 40 (3): 480-5. DOI: https://doi.org/10.1007/s11596-020-2203-3.
16. Zhou J., et al. Clinical characteristics of repositive COVID-19 patients in Huangshi, China: A retrospective cohort study. PLoS One. 2020; 15 (11): 1-15. DOI: https://doi.org/10.1371/journal.pone.0241896